Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (1321)	12/2/1997 10:57:00 AM
From: james	Read Replies (1) \| Respond to of 4676

thanks stan for the info. I am still not very convinced that telomease is a sound anti-cancer target. Clinical data suggests a strong link, but there is always the the concern of chick-egg. Hyper-activity of telomease might just be an accompanied event without any physiological revelancy. But diagnostics will be more profitable at this stage. Just 'gut-feeling' regards

To: squetch who wrote (1321)	12/2/1997 9:15:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4676

Stan: >>I think Whithead Inst. is ahead here, but am not certain. mz, will let us know I am sure.<< I have funny felling that I know something more or better than another me. :) Knowing few chemical structures or small part of old biochemistry are not of any advantage in today biotechnology field. To much over my head. I agree that Whithead Inst. have strong financial support from Merck and that they will do anything in their power to be first in telomerase field. On the other hand GERN have science support from Colorado U. and U. of T. , and they are serious player. Also, P&U is coming out from regression. Others will jump in. Majority of the important discovery/development will be hold as trade secret and we will be last to know what is going on. mz